-vikg for the treatment of neovascular age-related macular degeneration . The product was developed as a specific ocular formulation to overcome the sometimes controversial off-label use of existing bevacizumab products for wet AMD.. The drug, a humanized monoclonal antibody given by intravitreal injection, works by binding to vascular endothelial growth factor , preventing VEGF activity, and preserving vision.
The most common ocular adverse event was intravitreal injection–related conjunctival hemorrhage that resolved without complications, followed by eye pain, vitreous floaters, and increased intraocular pressure. The overall frequency of treatment-emergent ocular adverse events was similar in both groups at 45.1% vs 41.7%, respectively.AMD is the most common cause of visual impairment and blindness in Europe, with a pooled annual incidence of late-stage disease of 1.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: cbschicago - 🏆 546. / 51 Read more »
Source: sdut - 🏆 5. / 95 Read more »
Source: Gothamist - 🏆 456. / 53 Read more »
Source: bbchealth - 🏆 143. / 63 Read more »